Equasens

EQUASENS: 2022 Net Profit: +18.35% to €48.70m

24 Mar 2023 12:00:00 By Nasdaq GlobeNewswire

EQUASENS: FY 2022 revenue: +10.88% to €214.07m

03 Feb 2023 11:00:00 By Nasdaq GlobeNewswire

EQUASENS: H2 2022 HALF-YEAR REPORT ON THE LIQUIDITY AGREEMENT WITH GILBERT DUPONT

20 Jan 2023 11:00:00 By Nasdaq GlobeNewswire

EQUASENS: Appointment of Frédérique SCHMIDT as the Group’s Chief Administrative and Financial Officer

19 Jan 2023 11:00:00 By Nasdaq GlobeNewswire

EQUASENS GROUP: 2022 third-quarter revenue

09 Nov 2022 11:00:00 By Nasdaq GlobeNewswire

EQUASENS: subsidiary PANDALAB receives ISO 27001 and HDS certifications

18 Oct 2022 11:00:00 By Nasdaq GlobeNewswire

EQUASENS: H1 2022 Results

22 Sep 2022 11:00:00 By Nasdaq GlobeNewswire

EQUASENS (ex-Pharmagest Interactive): H1 2022 Revenue

03 Aug 2022 11:00:00 By Nasdaq GlobeNewswire

Equasens Group (ex Pharmagest Interactive): Complition of three majority acquisitions

28 Jul 2022 11:00:00 By Nasdaq GlobeNewswire

EQUASENS (ex Pharmagest Interactive): H1 2022 HALF-YEAR REPORT ON THE LIQUIDITY AGREEMENT WITH THE BROKERAGE FIRM GILBERT DUPONT

21 Jul 2022 11:00:00 By Nasdaq GlobeNewswire

EQUASENS (Ex Pharmagest Interactive): RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 28 JUNE 2022

06 Jul 2022 12:01:24 By Nasdaq GlobeNewswire

EQUASENS (ex Pharmagest Interactive) joins Euronext’s new TECH LEADERS segment

27 Jun 2022 00:00:00 By Nasdaq GlobeNewswire